Skip to main content

Amicus Therapeutics spins off genetic medicine unit in $600M SPAC deal

Amicus is spinning off part of its gene therapy business a year after establishing its gene therapy research center in Philadelphia.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.